Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Authors:
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (1) , 106-111
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential SynergiesCancer Immunology Research, 2015
- Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancerCancer Immunology, Immunotherapy, 2013
- Chemoimmunotherapy: reengineering tumor immunityCancer Immunology, Immunotherapy, 2013
- Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated MechanismsMolecular Therapy, 2010
- Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T CellsThe Journal of Immunology, 2003